GlassScriptPhysician profile
Meredith L Taylor
NPI 1013128693
$997.77
in general payments reported to CMS, 2019-2025
26 companies · $69.55 in 2025
The $69.55 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $175 · 2023: $189 · 2024: $67.01 · 2025: $69.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119.29 | 2019-2023 | Vraylar |
| Lilly USA, LLC | $90.37 | 2019-2020 | |
| Pfizer INC. | $74.73 | 2019-2023 | |
| Novo Nordisk INC | $74.24 | 2019-2023 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $69.43 | 2019 | |
| Glaxosmithkline, LLC. | $64.96 | 2019-2025 | Bexsero, Shingrix, Arexvy |
| Hologic Sales and Service, LLC | $63.96 | 2024-2025 | Omni Hysteroscope, Aptima |
| Novartis Pharmaceuticals Corporation | $61.96 | 2019-2020 | |
| Daiichi Sankyo INC. | $39.86 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.62 | 2019 | |
| Exact Sciences Corporation | $37.99 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $34.79 | 2020 | |
| Amgen INC. | $20.62 | 2019 | |
| Astellas Pharma US INC | $19.95 | 2019 | |
| Neurocrine Biosciences, INC. | $19.51 | 2023 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $18.55 | 2020 | |
| Sanofi Pasteur INC. | $18.45 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.42 | 2023 | |
| Cranial Technologies, INC | $17.60 | 2019 | |
| Genentech USA, INC. | $16.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.10 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.90 | 2019 | |
| Merck Sharp & Dohme LLC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.